Enabling IoT ecosystems through platform interoperability

Today, the Internet of Things (IoT) comprises vertically oriented platforms for things. Developers who want to use them need to negotiate access individually and adapt to the platform-specific API and information models. Having to perform these actions for each platform often outweighs the possible gains from adapting applications to multiple platforms. This fragmentation of the IoT and the missing interoperability result in high entry barriers for developers and prevent the emergence of broadly accepted IoT ecosystems. The BIG IoT (Bridging the Interoperability Gap of the IoT) project aims to ignite an IoT ecosystem as part of the European Platforms Initiative. As part of the project, researchers have devised an IoT ecosystem architecture. It employs five interoperability patterns that enable cross-platform interoperability and can help establish successful IoT ecosystems.Peer ReviewedPostprint (author's final draft

On the Effectiveness of Adversarial Samples against Ensemble Learning-based Windows PE Malware Detectors

Recently, there has been a growing focus and interest in applying machine learning (ML) to the field of cybersecurity, particularly in malware detection and prevention. Several research works on malware analysis have been proposed, offering promising results for both academic and practical applications. In these works, the use of Generative Adversarial Networks (GANs) or Reinforcement Learning (RL) can aid malware creators in crafting metamorphic malware that evades antivirus software. In this study, we propose a mutation system to counteract ensemble learning-based detectors by combining GANs and an RL model, overcoming the limitations of the MalGAN model. Our proposed FeaGAN model is built based on MalGAN by incorporating an RL model called the Deep Q-network anti-malware Engines Attacking Framework (DQEAF). The RL model addresses three key challenges in performing adversarial attacks on Windows Portable Executable malware, including format preservation, executability preservation, and maliciousness preservation. In the FeaGAN model, ensemble learning is utilized to enhance the malware detector's evasion ability, with the generated adversarial patterns. The experimental results demonstrate that 100\% of the selected mutant samples preserve the format of executable files, while certain successes in both executability preservation and maliciousness preservation are achieved, reaching a stable success rate

Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019

BACKGROUND: The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. METHODS: We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. FINDINGS: In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of −0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = −0.41), inflammatory bowel disease (AAPC = −0.72), multiple sclerosis (AAPC = −0.26), psoriasis (AAPC = −0.77), and atopic dermatitis (AAPC = −0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. INTERPRETATION: The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively. FUNDING: The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38)

Global, regional, and national incidence of six major immune-mediated inflammatory diseases : findings from the global burden of disease study 2019

DATA SHARING STATEMENT : Data used for the analyses are publicly available from the Institute of Health Metrics and Evaluation (http://www.healthdata.org/; http:// ghdx.healthdata.org/gbd-results-tool).BACKGROUND : The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. METHODS : We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. FINDINGS : In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of −0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = −0.41), inflammatory bowel disease (AAPC = −0.72), multiple sclerosis (AAPC = −0.26), psoriasis (AAPC = −0.77), and atopic dermatitis (AAPC = −0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. INTERPRETATION : The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively.The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. Support from Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital; Shaqra University; the School of Pharmacy, University of Botswana; the Indian Council of Medical Research (ICMR); an Australian National Health and Medical Research Council (NHMRC) Investigator Fellowship; the Italian Center of Precision Medicine and Chronic Inflammation in Milan; the Department of Environmental Health Engineering of Isfahan University of Medical Sciences, Isfahan, Iran; National Health and Medical Research Council (NHMRC), Australia; Jazan University, Saudi Arabia; the Clinician Scientist Program of the Clinician Scientist Academy (UMEA) of the University Hospital Essen; AIMST University, Malaysia; the Department of Community Medicine, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India; a Kornhauser Research Fellowship at The University of Sydney; the National Research, Development and Innovation Office Hungary; Taipei Medical University; CREATE Hope Scientific Fellowship from Lung Foundation Australia; the National Institute for Health and Care Research Manchester Biomedical Research Centre and an NIHR Clinical Lectureship in Respiratory Medicine; Kasturba Medical College, Mangalore and Manipal Academy of Higher Education, Manipal; Author Gate Publications; the Cleveland Clinic Foundation and Nassau University Medical center; the Italian Ministry of Health (RRC); King Abdulaziz University (DSR), Jeddah, and King Abdulaziz City for Science & Technology (KACSAT), Saudi Arabia, Science & Technology Development Fund (STDF), and US-Egypt Science & Technology joint Fund: The Academy of Scientific Research and Technology (ASRT), Egypt; partially supported by the Centre of Studies in Geography and Spatial Planning; the International Center of Medical Sciences Research (ICMSR), Islamabad Pakistan; Ain Shams University and the Egyptian Fulbright Mission Program; the Belgian American Educational Foundation; Health Data Research UK; the Spanish Ministry of Science and Innovation, Institute of Health Carlos III, CIBERSAM, and INCLIVA; the Clinical Research Development Unit, Imam Reza Hospital, Mashhad University of Medical Sciences; Shaqra University; Saveetha Institute of Medical and Technical Sciences and SRM Institute of Science and Technology; University of Agriculture, Faisalabad-Pakistan; the Chinese University of Hong Kong Research Committee Postdoctoral Fellowship Scheme; the institutional support of the Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Egypt; the European (EU) and Developing Countries Clinical Trials Partnership, the EU Horizon 2020 Framework Programme, UK-National Institute for Health and Care Research, the Mahathir Science Award Foundation and EU-EDCTP.http://www.thelancet.comam2024School of Health Systems and Public Health (SHSPH)SDG-03:Good heatlh and well-bein

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

This online publication has been corrected. The corrected version first appeared at thelancet.com on September 28, 2023BACKGROUND : Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050. METHODS : Estimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively. FINDINGS : In 2021, there were 529 million (95% uncertainty interval [UI] 500–564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6·1% (5·8–6·5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7–9·9]) and, at the regional level, in Oceania (12·3% [11·5–13·0]). Nationally, Qatar had the world’s highest age-specific prevalence of diabetes, at 76·1% (73·1–79·5) in individuals aged 75–79 years. Total diabetes prevalence—especially among older adults—primarily reflects type 2 diabetes, which in 2021 accounted for 96·0% (95·1–96·8) of diabetes cases and 95·4% (94·9–95·9) of diabetes DALYs worldwide. In 2021, 52·2% (25·5–71·8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24·3% (18·5–30·4) worldwide between 1990 and 2021. By 2050, more than 1·31 billion (1·22–1·39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16·8% (16·1–17·6) in north Africa and the Middle East and 11·3% (10·8–11·9) in Latin America and Caribbean. By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%. INTERPRETATION : Diabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers.Bill & Melinda Gates Foundation.http://www.thelancet.comam2024School of Health Systems and Public Health (SHSPH)SDG-03:Good heatlh and well-bein

Antibacterial efficacy of greenly synthesized silver nanoparticles using nanocurcumin and silver nanoparticle gel on bovine mastitis

This study summarizes the synthesis of AgNPs using nanocurcumin as a reducing and stabilizing agent (CurAgNPs). The stability of CurAgNPs after 12 months of storage and their antimicrobial activity against four bacteria causing mastitis in cows were investigated. Ultraviolet — visible (UV–vis) spectroscopy of the dark brownish-red stabilized CurAgNPs solution decating the surface plasmon resonance peak of the sample was observed at 438 nm. Images of the spherical CurAgNPs were obtained using transmission electron microscopy (TEM), which showed a mean particle size distribution of 15–58 nm, with a mean size of 32 nm. The influence of CurAgNPs on four microorganisms that cause mastitis in cows, Streptococcus agalactiae ( S. agalactiae ), Staphylococcus aureus ( S. aureus ), Pseudomonas aeruginosa ( P. aeruginosa ), and Eschericia coli ( E. coli ), was studied, and the minimum inhibitory concentration (MIC) was from 1.6 to 6.25 ppm. From this, the MBC of CurAgNPs were observed at 3.15 ppm for S. agalactiae , and 6.25 ppm for S. aureus , P. aeruginosa and E. coli , respectively. The formulated homogeneous gel containing 100 ppm CurAgNPs, 1.5% carboxymethyl cellulose (CMC), and distilled water was developed with a viscosity of 141 ± 7.55 cP, pH of 6.72 ± 0.11, and homogenized. The zeta potential of CurAgNPs gel after 6 months of storage is almost constant. In addition, the improved CurAgNPs gel demonstrated significant antimicrobial activity compared with tetracycline at a concentration of 100 ppm

SOLUTIONS TO IMPROVE AWARENESS AND IMPROVE KNOWLEDGE, ATTITUDE, PRACTICE (KAP) ABOUT COVID-19 FOR ETHNIC MINORITY PEOPLES IN GIA LAI PROVINCE, VIETNAM

COVID-19 is a global health threat and an international public health emergency. Right awareness, good knowledge, positive attitude, and good practice are one of the central issues to ensure the successful prevention and control of the COVID-19 pandemic. However, in some remote rural areas with difficult living conditions, social media about COVID-19 has not reached them. So, this study aims to present a possible solution to improve their awareness about COVID-19 among ethnic minorities in Gia Lai province, Vietnam. This study was conducted with 674 people in the community from September 1 to December 20, 2021. An intervention design using the stratified communication model and structured questionnaire was used to collect information regarding sociodemographic characteristics, knowledge (eight questions), attitudes (three questions), and practice (three questions). Of the total study participants, 64.31% were female and 95% lived in rural areas. The results showed that the poor knowledge, attitude and practice of the before intervention group improved compared to the after intervention and compared with the control group significantly increased with P < 0.05. Therefore, health education programs to improve awareness and raise KAP about COVID-19 are essential, especially for illiterate people, poor people, and a lack of means to communicate.&nbsp

Enabling IoT ecosystems through platform interoperability

Today, the Internet of Things (IoT) comprises vertically oriented platforms for things. Developers who want to use them need to negotiate access individually and adapt to the platform-specific API and information models. Having to perform these actions for each platform often outweighs the possible gains from adapting applications to multiple platforms. This fragmentation of the IoT and the missing interoperability result in high entry barriers for developers and prevent the emergence of broadly accepted IoT ecosystems. The BIG IoT (Bridging the Interoperability Gap of the IoT) project aims to ignite an IoT ecosystem as part of the European Platforms Initiative. As part of the project, researchers have devised an IoT ecosystem architecture. It employs five interoperability patterns that enable cross-platform interoperability and can help establish successful IoT ecosystems.Peer Reviewe